1. Home
  2. Browse
  3. National Institutes of Health
  4. PAR-25-101

PAR-25-101National Institutes of HealthR21

Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional)

Deadline
Award ceiling
$150,000
Awards
Not stated
Posted
Dec 30, 2024

Official announcement on the NIH Guide · opens the funder's page. Always confirm dates there.

Or read the full text and all 3 standing review criteria here, free with an account. Create free account

Summary

The National Institute on Drug Abuse (NIDA) Cutting-Edge Basic Research Award (CEBRA) is designed to foster highly innovative or conceptually creative research related to the etiology, pathophysiology, prevention, or treatment of substance use disorders (SUDs)…

Related NIH announcements1

Other open R21 announcements on related subjects, with at least two weeks to go.

Accelerating the Pace of Substance Use Research Using Existing Data (R21 Clinical Trial Not Allowed)

RFA-DA-26-056National Institutes of Health3 review criteria on fileagency framework

—

The full announcement, free with an account

  • The full announcement text, not just the first two sentences
  • All 3 standing review criteria National Institutes of Health applies to this kind of proposal (its standard framework, not criteria written for this announcement)

On Plus, $39 a month

  • The eligibility check against your profile: career stage, institution type, and the windows that close before the deadline does
  • Funded precedents: what similar NIH projects received, from the award records in NIH RePORTER
  • A Reviewer Scorecard of your draft against these criteria
Create free accountSign in

No card required. Browsing is free.

Subjects

More from National Institutes of Health

Open now with at least two weeks to apply, soonest deadline first.

Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)

RFA-DK-27-112National Institutes of Health

—

NIDCR Behavioral and Social Intervention Clinical Trial Planning and Implementation Cooperative Agreement (UG3/UH3 Clinical Trial Required)

PAR-25-188National Institutes of Health3 review criteria on file

$500k

Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)

RFA-DK-27-139National Institutes of Health

—

Continuation of the Cardiovascular Repository for-Type 1 Diabetes (CARE-T1D) Consortium U01 (Open Competition)- Research (U01, Clinical Trial Not Allowed)

RFA-DK-27-108National Institutes of Health3 review criteria on fileagency framework

$500k

Everything open from National Institutes of Health

Related by subject

Open opportunities sharing the most subjects with this one (Substance use), with at least two weeks to apply.

NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional)

PAR-24-089National Institutes of Health5 review criteria on fileagency framework

$750k

D-START: Data Science Track Award for Research Transition (D/START) (R03-Clinical Trial Optional)

PAS-25-236National Institutes of Health3 review criteria on fileagency framework

—

OJJDP FY 2026 Expanding Youth Access to Community-Based Treatment

O-OJJDP-2026-172737Office of Juvenile Justice Delinquency Prevention

$650k

Everything open tagged Substance use

Source record: https://grants.nih.gov/grants/guide/pa-files/PAR-25-101.htmlVia the NIH Guide. Last checked against the source . Always confirm dates with the funder.